Onxeo S.A.: Publication of a Shareholders Letter

PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE)-- Regulatory News:

Onxeo S.A. (Paris: ONXEO) (NASDAQ OMX: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announces the publication of a Shareholders Letter (1).

This Shareholders Letter updates on major achievements of the first half of 2015 and on the company’s short and middle term catalysts.

(1) The Shareholders Letter is available on the website at: www.onxeo.com (News or Medias).

About OnxeoOnxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to “make the difference”. The Onxeo teams are determined to develop innovative medicines to provide patients with hope and significantly improve their lives.

Key orphan oncology products at the advanced development stage are:Livatag® (doxorubicin Transdrug™): Phase III in hepatocellular carcinomaValidive® (clonidine Lauriad®): Phase II in severe oral mucositis: Positive final resultsBeleodaq® (belinostat): registered in the US in 2nd line treatmentof peripheral T-cell lymphomaFor more information, visit the website www.onxeo.com

To receive our press releases and newsletters, please register on: http://www.onxeo.com/en/newsletter/Follow us on twitter @Onxeo_

DisclaimerThis communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2014 Reference Document filed with the AMF on April 14, 2015, which is available on the AMF website (http://www.amf-france.org) or on the company’s website (www.onxeo.com).

View source version on businesswire.com: http://www.businesswire.com/news/home/20150903006116/en/

Onxeo S.A.
Judith Greciet, CEO
[email protected]
Nicolas Fellmann, CFO
[email protected]
+33 1 45 58 76 00
Caroline Carmagnol and Florence Portejoie
[email protected]
+33 6 64 18 99 59 / +33 6 47 38 90 04

Source: Onxeo S.A.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• AUSTRALIAN OLYMPIAN CAMRYN NEWTON-SMITH CROWNED "WORLD'S GREATEST ATHLETE" IN WOMEN'S DECATHLON WORLD CHAMPIONSHIPS
• CORRECTION: Purple Heart Homes Launches Historic National Mall Veteran Home Build During America's 250th Anniversary
• AquaShine Express Voted Best Car Wash in South Carolina in the 2026 Best of South Carolina Awards, Its Second Consecutive Statewide Win